155 results on '"Henry, A. L."'
Search Results
2. Living Donors with Impaired Fasting Glucose – Too Sweet?
3. Evaluation of Flagging Criteria of United States Kidney Transplant Center Performance
4. Effects of Cardiovascular Comorbidity Adjustment on SRTR Risk-Adjusted Cox Proportional Hazard Models of Graft Survival
5. Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients
6. Steroid-Free Maintenance Immunosuppression With Rapamune and Low-Dose Neoral in Pancreas Transplant Recipients
7. Improving the Prediction of Donor Kidney Quality: Deceased Donor Score and Resistive Indices
8. Molmenti Technique of Hepatic and Pancreatic Vascular Reconstruction
9. Procurement of Liver and Pancreas Allografts in Donors with Replaced/Accessory Right Hepatic Arteries
10. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation
11. DELAYED CYCLOSPORINE ADMINISTRATION FOLLOWING SIMULECT INDUCTION DOES NOT INCREASE ACUTE REJECTION IN RENAL TRANSPLANT RECIPIENTS.
12. BASILIXIMAB VS OKT3 IN PRIMARY SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS.
13. IMPROVED OUTCOME IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIMULECT VERSUS OKT3 INDUCTION.
14. RANDOMIZED, PROSPECTIVE TRIAL OF PREDNISONE WITHDRAWAL IN STABLE RENAL TRANSPLANT RECIPIENTS.
15. IMPROVED PATIENT SURVIVAL IN HIGH RISK RENAL TRANSPLANT (RTx) RECIPIENTS TREATED WITH HMG CoA REDUCTASE INHIBITORS (HMG): AN EFFECT INDEPENDENT OF SERUM LIPID LEVELS.
16. IMMEDIATE RENAL ALLOGRAFT FUNCTION FOLLOWING PULSATILE PRESERVATION.
17. BASILIXIMAB VS OKT3 IN LIVER TRANSPLANTATION.
18. OBESE LIVING KIDNEY DONORS: SHORT-TERM RESULTS AND POSSIBLE IMPLICATIONS1
19. MEDICATION COMPLIANCE FOLLOWING RENAL TRANSPLANTATION
20. SIMULECT AND DELAYED NEORAL IN LIVER AND KIDNEY/PANCREAS TRANSPLANTATION
21. IL-2r ANTIBODY INDUCTION WITH DELAYED NEORAL THERAPY.
22. CHANGES IN THE CLINICAL CHARACTERISTICS OF POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) IN KIDNEY AND SIMULTANEOUS PANCREAS-KIDNEY RECIPIENTS (SPK).
23. COMPARISON OF NON-LIPITOR AND LIPITOR THERAPY FOR TREATMENT OF HYPERLIPIDEMIA IN KIDNEY TRANSPLANT RECIPIENTS.
24. EARLY GRAFT FUNCTION AFTER IN SITU LR FOLLOWED BY BACKTABLE ORGAN PERFUSION WITH UW
25. PATHOLOGIC CLASSIFICATION OF CHRONIC ALLOGRAFT NEPHROPATHY: PATHOGENIC AND PROGNOSTIC IMPLICATIONS1
26. INCREASED INCIDENCE OF GASTROINTESTINAL SURGICAL COMPLICATIONS IN RENAL TRANSPLANT RECIPIENTS WITH POLYCYSTIC KIDNEY DISEASE1
27. RANDOMIZED MULTICENTER OPEN LABEL COMPARATIVE TRIAL OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION
28. A PROSPECTIVE RANDOMIZED TRIAL OF NEORAL AND CELLCEPT WITH AND WITHOUT OKT3 INDUCTION
29. The Older Renal Transplant Recipient: Advantage or Disadvantage of Decreased Clinical Immune Responsiveness
30. CLINICAL IMPLICATIONS OF THE DIAGNOSIS OF RENAL ALLOGRAFT INFARCTION BY PERCUTANEOUS BIOPSY1
31. LOW-DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEi) ARE SAFE AND EFFECTIVE IN REDUCING PROTEINURIA (UPROT) IN RENAL ALLOGRAFT RECIPIENTS.
32. ANTIBODY INDUCTION IN THE CURRENT ERA
33. FUNCTION AND SURVIVAL OF RENAL ALLOGRAFTS FROM THE SAME DONOR TRANSPLANTED INTO KIDNEY-ONLY OR KIDNEY-PANCREAS RECIPIENTS1
34. IMPACT OF ACUTE REJECTION AND EARLY ALLOGRAFT FUNCTION ON RENAL ALLOGRAFT SURVIVAL
35. CLINICAL AND ECONOMIC IMPACT OF FLOW CYTOMETRY CROSSMATCHING IN PRIMARY CADAVERIC KIDNEY AND SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1
36. FACTORS RELATED TO THE DONOR ORGAN ARE MAJOR DETERMINANTS OF RENAL ALLOGRAFT FUNCTION AND SURVIVAL
37. THE HIGH PREVALENCE OF SEVERE EARLY POSTTRANSPLANT RENAL ALLOGRAFT PATHOLOGY IN HEPATITIS C POSITIVE RECIPIENTS
38. OBESITY AS A RISK FACTOR AFTER COMBINED PANCREAS/KIDNEY TRANSPLANTATION1
39. IMPACT OF SERUM LIPIDS ON LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION1
40. THE FREQUENCY OF REJECTION EPISODES AFTER COMBINED KIDNEY-PANCREAS TRANSPLANT—THE IMPACT ON GRAFT SURVIVAL
41. TRANSMISSION OF HEPATITIS C BY KIDNEY TRANSPLANTATION—THE RISKS1
42. OKT3 FOR PRIMARY THERAPY OF THE FIRST REJECTION EPISODE IN KIDNEY TRANSPLANTS
43. A RANDOMIZED, PROSPECTIVE, DOUBLE-BLINDED TRIAL OF CYCLOSPORINE VS. OG37–325 IN CADAVERIC RENAL TRANSPLANTATION—A PRELIMINARY REPORT
44. WHOLE-ORGAN TRANSPLANT OF AN ANNULAR PANCREAS
45. RANDOMIZED, PROSPECTIVE TRIAL OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION AFTER SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION12.
46. OBESE LIVING KIDNEY DONORS: SHORT-TERM RESULTS AND POSSIBLE IMPLICATIONS1.
47. PATHOLOGIC CLASSIFICATION OF CHRONIC ALLOGRAFT NEPHROPATHY: PATHOGENIC AND PROGNOSTIC IMPLICATIONS1.
48. OBESITY AS A RISK FACTOR AFTER COMBINED PANCREAS/KIDNEY TRANSPLANTATION1.
49. IMPACT OF SERUM LIPIDS ON LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION1.
50. TRANSMISSION OF HEPATITIS C BY KIDNEY TRANSPLANTATION—THE RISKS1.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.